Mark Ebell News Today

The cost, time burden, and potential side effects of a new Alzheimer's drug may not be worth the minimal benefit, research suggests.

Cost, time burden and side effects may not be worth the minimal benefit.

Researchers are reporting that the risks from monoclonal antibody treatments for Alzheimer's appear to outweigh the benefits, so these therapies probably people shouldn't be used on most people with the disease

The effectiveness of a new drug used to treat Alzheimer’s was called into question by a recent University of Georgia study, according to a Jan. 22 press release.

Almost a quarter of Americans now opt for a telehealth visit.

The use of insulin pumps and glucose monitors may help people with pregestational diabetes.

People taking aspirin are more likely to develop advanced cancers that may lead to their death

11Alive's Jerry Carnes reports.

Fears of a one-two punch from COVID-19 and the flu didn’t happen last year, but experts warn the likelihood of a “twindemic” is higher this winter.

Fears of a one-two punch from COVID-19 and the flu didn’t happen last year, but experts warn the likelihood of a “twindemic” is higher this winter.